SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study

J Taieb,T Price,L Wyrwicz,L Vidot,A Raimond-Thibaut,H Chrostek,J Bachet,A Falcone

doi:10.1016/j.annonc.2021.05.042

SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study

J Taieb, T Price + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2021.05.042

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jul 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Queen Elizabeth Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Servier (France), Sorbonne Université, Azienda Ospedaliera Universitaria Pisana, University of Pisa

#Phase IIIb Trial #Phase IIIb + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Trifluridine/tipiracil (FTD/TPI) is registered in over 93 countries for the management of patients with metastatic colorectal cancer (mCRC) who have progressed on standard therapies. In the RECOURSE study, FTD/TPI significantly improved overall survival and progression-free survival (PFS) compared with placebo. 1,2 PRECONNECT was an international, multicentre, open-label, phase IIIb trial (NCT03306394) designed to provide eligible adults with mCRC access to FTD/TPI and to further characterise the safety and efficacy of FTD/TPI in daily clinical practice.

Full Text